Beyond risk prediction, increasing evidence links Cav-3/caveolae to HF-relevant pathophysiology, including arrhythmia susceptibility and insulin-signaling defects in ischemic or metabolic heart disease—both potential treatment targets (5, 24). Here, CAV3 is linked to hydrops fetalis.